Lowering LDL-C for optimal protection in high-risk patients.
Shaley
Frank M
FM
D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D000069059:Atorvastatin; D008078:Cholesterol, LDL / Q000097:blood* / Q000187:drug effects; D003324:Coronary Artery Disease / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000517:prevention & control; D019983:Guideline Adherence; D006538:Heptanoic Acids / Q000008:administration & dosage; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D017035:Pravastatin / Q000008:administration & dosage; D011758:Pyrroles / Q000008:administration & dosage; D018570:Risk Assessment
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin; D017035:Pravastatin